RBQM Operations 2022 To Take Place From 27-28 September, Using vFairs Event Technology

This virtual event will discuss the big challenges in implementing Risk-Based Quality Management (RBQM) in clinical research. 

Cambridge, UK –  TRI will host RBQM Operations 2022 on the 27th and 28th of September, 2022. This virtual event is aimed at anyone involved in clinical research in the pharmaceutical industry. These individuals and companies can learn about RBQM and its impact on clinical operations at this event. So, they should register here to expand their knowledge base on the subject. 

The event will help pharmaceutical companies improve the efficiency, effectiveness, and data quality of their trials.  According to the Association of Clinical Research Organizations (ACRO), in their 2021 review of 4,889 ongoing studies, 88% had at least one RBQM element, up from 53% in 2019. 57% were Phase I or II, and 59% had fewer than 300 patients. For new studies starting in 2021, 91% now have an initial Risk Assessment and 86% planned ongoing Risk Assessments, up from 84% and 83% respectively in 2019. Only 43% of new studies have Centralized Monitoring, up from 31% in 2019. So, while the takeup of RBQM in new studies is increasing, there’s still a long way to go to get 100% coverage.

This is one of the biggest hurdles in the pharmaceutical sector, and RBQM Operations 2022 will be helpful in demonstrating best practices in a practical manner, not just theoretically. There will be a number of Sponsors and CROs present to share their real-world experiences, and how they’ve addressed the major challenges they see in RBQM today. 

Neil Watkins, Chief Marketing Officer at TRI, said, “RBQM Operations 2022 is for anyone involved in clinical trials. We’re going to be diving into some of the biggest RBQM challenges facing the industry, both now and in the future. We’re excited to have industry experts to share their insights and practical lessons learned implementing RBQM and how they’ve overcome these challenges. Please register today to reserve your spot and we look forward to seeing you in September.”

Muhammad Younas, CEO & Founder at vFairs, added, “Pharmaceutical research is one of the most important sectors in current times. So, it is great to see how companies are utilizing virtual event solutions to help make the research process more efficient and implementable.”

RBQM Operations 2022 will take place on September 27 and 28. Anyone interested can register for free here

About TRI

TRI aims to make RBQM simple and accessible for every clinical trial. Based in Cambridge, UK and Raleigh, NC USA, it serves Sponsors and CROs with industry-leading RBQM solutions, technology, training and support. Go to www.tritrials.com for more information.

Acerca de vFairs

vFairs es una plataforma de eventos virtuales, híbridos y presenciales que ayuda a organizaciones de todos los tamaños, sectores y regiones a celebrar eventos en línea memorables para lograr resultados empresariales reales. La plataforma virtual y la aplicación móvil ofrecen funciones versátiles y opciones de personalización. También ofrecen un excepcional servicio de atención al cliente, calificado sistemáticamente como el número 1 en sitios de terceros como G2 y Capterra. Esta es la razón por la que las principales organizaciones de todo el mundo han elegido vFairs para celebrar conferencias virtuales, ferias comerciales en línea, ferias de empleo, formación virtual y mucho más.

RBQM Operations 2022 To Take Place From 27-28 September, Using vFairs Event Technology

Shanzay Asim Haider

Shanzay Asim Haider es redactora de contenidos con más de 5 años de experiencia. Le encanta aprender y escribe para vFairs por el apasionante potencial del sector de los eventos virtuales e híbridos. Entre sus aficiones se encuentran la lectura (por supuesto), los rompecabezas y los juegos de mesa demasiado complicados.

Organice su evento virtual, híbrido y presencial

Nuestros ágiles gestores de proyectos ofrecen asistencia integral para ayudarle a organizar experiencias increíbles para su público.